First National Bank of Omaha Purchases 8,167 Shares of AbbVie Inc. $ABBV

Key Points

• First National Bank of Omaha increased its AbbVie stake by 21.2% in the second quarter, purchasing 8,167 additional shares for a total of 46,685 shares valued at approximately $11.8 million. Institutional investors collectively own 70.23% of ABBV.
• Analysts maintain a generally positive outlook, with AbbVie receiving a “Moderate Buy” consensus rating and an average price target of $275.95. The company recently exceeded quarterly earnings and revenue expectations, reporting $3.65 in EPS and $16.99 billion in revenue.
• AbbVie pays a quarterly dividend of $1.73 per share, equating to a 2.7% yield, while shares trade near their 52-week high. Investors should also weigh valuation concerns and an executive sale of 32,710 shares worth about $8.2 million.

First National Bank of Omaha increased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 21.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,685 shares of the company's stock after purchasing an additional 8,167 shares during the period. First National Bank of Omaha's holdings in AbbVie were worth $11,773,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. ACT Advisors LLC. grew its stake in AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after buying an additional 41 shares during the last quarter. Willner & Heller LLC lifted its position in AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after acquiring an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC boosted its holdings in AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after acquiring an additional 43 shares during the period. Fielder Capital Group LLC boosted its holdings in AbbVie by 1.7% during the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock valued at $637,000 after acquiring an additional 43 shares during the period. Finally, Leslie Global Wealth LLC grew its position in shares of AbbVie by 1.5% in the second quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock valued at $751,000 after purchasing an additional 44 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ABBV shares. Erste Group Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. Piper Sandler boosted their price target on AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a report on Tuesday, June 23rd. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. Finally, Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 5th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and an average target price of $275.95.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $256.08 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The company has a market capitalization of $452.44 billion, a PE ratio of 72.34, a PEG ratio of 0.86 and a beta of 0.30. The company has a 50 day moving average price of $252.66 and a two-hundred day moving average price of $228.87.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company's revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
• Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial
• Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year
• Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy?

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source